CLINICAL TRIALS PROFILE FOR LY3372689
✉ Email this page to a colleague
Clinical Trials for LY3372689
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT03819270 ↗ | A Safety Study of LY3372689 Given By Mouth to Healthy Participants | Completed | Eli Lilly and Company | Phase 1 | This study is being conducted to determine the safety profile of the study drug after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3372689 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive up to 3 doses of LY3372689 or placebo. The study will last about 12 weeks, including screening. |
| NCT03944031 ↗ | A Study of the Effects of LY3372689 on the Brain in Healthy Participants | Completed | Eli Lilly and Company | Phase 1 | This study uses imaging to evaluate how LY3372689 binds to a protein in the brain. This study will be conducted in healthy participants and will last up to approximately 25 days after enrollment. Screening must be completed within 28 days prior to enrollment. |
| NCT04106206 ↗ | A Safety Study of LY3372689 in Healthy Participants | Completed | Eli Lilly and Company | Phase 1 | This study is being conducted to determine the safety profile of the study drug after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3372689 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive multiple doses of LY3372689 or placebo and will remain in the study for up to eight weeks. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for LY3372689
Condition Name
Clinical Trial Locations for LY3372689
Trials by Country
Clinical Trial Progress for LY3372689
Clinical Trial Phase
Clinical Trial Sponsors for LY3372689
Sponsor Name
